A Phase II Study of Preradiotherapy Chemotherapy Followed by Hyperfractionated Radiotherapy for Newly Diagnosed High-Risk Medulloblastoma/Primitive Neuroectodermal Tumor: A Report From the Children's Oncology Group (CCG 9931)

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 4, 2009, Pages 1006-1011

  Allen, Jeffrey ^a   Donahue, Bernadine ^b   Mehta, Minesh ^c   Miller, Douglas C ^a   Rorke, Lucy B ^d   Jakacki, Regina ^e   Robertson, Patricia ^f   Sposto, Richard ^g   Holmes, Emi ^h   Vezina, Gilbert ⁱ   Muraszko, Karin ^j   Puccetti, Diane ^k   Prados, Michael ^l   Chan, Ka Wah ^m  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b MAIMONIDES MEDICAL CENTER   (United States)

^c Children's Hospital ^*  (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h CHILDREN S ONCOLOGY GROUP   (United States)

ⁱ CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^j UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^k University of Wisconsin Children's Hospital   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m Methodist Children's Hospital of South Texas   (United States)

more..

Author keywords

Hyperfractionated radiotherapy; Medulloblastoma (high risk); PNET; Preradiation chemotherapy

Indexed keywords

CARBOPLATIN; CIS-PLATIN; ETOPOSIDE; HIGH DOSE; HYPERFRACTIONATED RADIOTHERAPY; MEDULLOBLASTOMA; MEDULLOBLASTOMA (HIGH RISK); MULTI-MODALITY; NEUROECTODERMAL TUMORS; OVERALL SURVIVAL; OVERALL SURVIVAL RATES; PHASE II; PNET; PRERADIATION CHEMOTHERAPY; PROGRESSION FREE SURVIVAL; PROGRESSIVE DISEASE; PROTOCOL DESIGN; RESIDUAL DISEASE; STUDY GROUPS; SURVIVAL DATA;

CHEMOTHERAPY; ONCOLOGY; PLATINUM COMPOUNDS; RADIOTHERAPY;

TUMORS;

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; FEASIBILITY STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NEUROECTODERM TUMOR; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; ETOPOSIDE; FEASIBILITY STUDIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MEDULLOBLASTOMA; NEUROECTODERMAL TUMORS, PRIMITIVE; VINCRISTINE; YOUNG ADULT;

EID: 67649544672     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.09.019     Document Type: Article

References (26)

1. Zeltzer P.M., Boyett, Finlay J., et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17 (1999) 832-845
2. Packer R.J., Gajjar A., Vezina G., et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24 (2006) 4202-4208
3. Hertzberg H., Huk W., Ueberall M., et al. CNS late effects after ALL therapy in childhood. Part I: Neuroradiological findings in long-term survivors of childhood ALL-an evaluation of the interferences between morphology and neuropsychological performance. The German Late Effects Working Group. Med Pediatr Oncol 28 (1997) 387-400
4. Allen J.C., Walker R., and Rosen G. Preradiation high-dose intravenous methotrexate with leucovorin rescue for untreated primary childhood brain tumors. J Clin Oncol 6 (1988) 649-653
5. Schell M.J., McHaney H., Green A., et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 7 (1989) 754-760
6. Kuhl J., Muller H., Berthold F., et al. Preradiation chemotherapy of children and young adults with malignant brain tumors: Results of the German pilot trial HIT'88/'89. Klin Padiatr 210 (1998) 227-233
7. Hartsell W.F., Gajjar A., Heideman R., et al. Patterns of failure in children with medulloblastoma: Effects of preirradiation chemotherapy. Int J Radiat Oncol Biol Phys 39 (1997) 15-24
8. Back M., Ahern V., Berry M., et al. Importance of radiation time and dose factors on outcome for childhood medulloblastoma. Australas Radiol 49 (2005) 298-303
9. Allen J.C., Donahue B., DaRosso R., et al. Hyperfractionated craniospinal radiotherapy and adjuvant chemotherapy for children with newly diagnosed medulloblastoma and other primitive neuroectodermal tumors. Int J Radiat Oncol Biol Phys 36 (1996) 1155-1161
10. Prados M.D., Edwards M., Chang S., et al. Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: Results of a Phase II study. Int J Radiat Oncol Biol Phys 43 (1999) 279-285
11. Jakacki R.I., Zelter P., Boyett J., et al. Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: A report of the Childrens Cancer Group. J Clin Oncol 13 (1995) 1377-1383
12. Castello M.A., Clerico A., Deb G., et al. High-dose carboplatin in combination with etoposide (JET regimen) for childhood brain tumors. Am J Pediatr Hematol Oncol 12 (1990) 297-300
13. Kalbfleisch J., and Prentice R. The statistical analysis of failure time data (1980), John Wiley & Sons, New York
14. Gajjar A., Chintagumpala M., Ashley D., et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 7 (2006) 813-820
15. Allen J.C., Helson L., and Jereb B. Preradiation chemotherapy for newly diagnosed childhood brain tumors. A modified Phase II trial. Cancer 52 (1983) 2001-2006
16. Mosijczuk A.D., Nigro M., Thomas P., et al. Preradiation chemotherapy in advanced medulloblastoma. A Pediatric Oncology Group pilot study. Cancer 72 (1993) 2755-2762
17. Heideman R.L., Kovnar E., Kellie S., et al. Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors. J Clin Oncol 13 (1995) 2247-2254
18. Kortmann R.D., Timmermann B., Becker G., et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 46 (2000) 269-279
19. Taylor R.E., Bailey C., Robinson K., et al. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 41 (2005) 727-734
20. Thames Jr. H.D., Withers H., Peters L., et al. Changes in early and late radiation responses with altered dose fractionation: Implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 8 (1982) 219-226
21. Barton M. Tables of equivalent dose in 2 Gy fractions: A simple application of the linear quadratic formula. Int J Radiat Oncol Biol Phys 31 (1995) 371-378
22. Carrie C., Muracciole X., Gomez F., et al. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: Results of the French M-SFOP 98 protocol. Int J Radiat Oncol Biol Phys 63 (2005) 711-716
23. Chin D., Sklar C., Donahue B., et al. Thyroid dysfunction as a late effect in survivors of pediatric medulloblastoma/primitive neuroectodermal tumors: A comparison of hyperfractionated versus conventional radiotherapy. Cancer 80 (1997) 798-804
24. Ricardi U., Corrias A., Einaudi S., et al. Thyroid dysfunction as a late effect in childhood medulloblastoma: A comparison of hyperfractionated versus conventionally fractionated craniospinal radiotherapy. Int J Radiat Oncol Biol Phys 50 (2001) 1287-1294
25. Mu X., Bjork-Eriksson T., Nill S., et al. Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatment planning study. Acta Oncol 44 (2005) 554-562
26. Yuh G.E., Loredo L., Yonemoto L., et al. Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. Cancer J 10 (2004) 386-390